<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093300</url>
  </required_header>
  <id_info>
    <org_study_id>HOST-ISR trial</org_study_id>
    <nct_id>NCT01093300</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In-stent restenosis (ISR) lesions are considered one of the toughest lesions that
      interventional cardiologists encounter in the drug eluting stent (DES) era. The current
      consensus in treating ISR is implantation of another DES into the restenosed segment. However
      the recent results of paclitaxel-releasing balloon catheter (PRBC) in ISR lesions have been
      very encouraging. The aim of HOST-ISR trial is to investigate the efficacy and safety of PRBC
      compared with everolimus-eluting stent (EES) in preventing neointimal growth in ISR lesions.
      HOST-ISR trial is a multicenter, open-label, prospective, randomized trial to test whether
      PRBC is non-inferior to EES in preventing neointimal growth in ISR lesions. It plans to
      enroll a total of 264 patients with ISR, randomizing the cohort 1:1 to either PRBC or EES.
      The primary endpoint will be in-segment late luminal loss at 9 months angiographical
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late luminal loss in the analysis segment</measure>
    <time_frame>9 months</time_frame>
    <description>Analysis segment is defined as +/- 5mm of the previous stented/inflated segment of the vessel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss in the inflation/in-stent segment</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion/vessel revascularization, myocardial infarction</measure>
    <time_frame>1, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural myocardial infarction</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% diameter stenosis in the analysis segment &amp; in the inflation/in-stent segment</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal volume, % neointimal volume, % volume obstruction</measure>
    <time_frame>9 months</time_frame>
    <description>The above parameters will be assessed by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval from device insertion to initiation of deployment</measure>
    <time_frame>0 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1, 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>In-stent Restenosis Lesion</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel-eluting balloon catheter use for treatment of ISR lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting stent use for treatment of ISR lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting balloon catheter</intervention_name>
    <arm_group_label>Paclitaxel-eluting balloon catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent</intervention_name>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18y

          -  Significant ISR lesion (&gt;50% by visual estimate) of previously stented de novo
             coronary artery

          -  Evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction,
             silent ischemia, positive functional study or a reversible changes in the
             electrocardiogram (ECG) consistent with ischemia) or ISR with diameter stenosis &gt; 70%

          -  Written, informed consent

          -  Target lesion(s) located in a native coronary artery within a previously stented
             lesion with previous stent diameter of ≥ 2.5 mm and ≤ 4.00 mm

          -  Target lesion(s) amenable for percutaneous coronary intervention

        Exclusion Criteria:

          -  Hypersensitivity to aspirin, clopidogrel, heparin, sirolimus, paclitaxel or
             radiocontrast media

          -  Systemic sirolimus use within 12 months

          -  Female of childbearing potential

          -  History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia)

          -  Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery
             within 2 months

          -  Non-cardiac co-morbid conditions present with life expectancy &lt;1 year or that may
             result in protocol non-compliance

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period

          -  ISR of left main coronary artery

          -  Restenosis of two stented bifurcation lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyung-Woo Park, MD, PhD</last_name>
    <phone>82-2-2072-2044</phone>
    <email>kwparkmd@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <phone>82-2-2072-2226</phone>
    <email>hyosoo@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hyo-Soo Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Seoul National University Hospital IRB</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

